샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744854

세계의 RNAi 약물전달 시장

RNAi Drug Delivery
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 294 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 RNAi 약물전달 시장은 2030년까지 33억 달러에 도달

2024년에 11억 달러로 추정되는 세계의 RNAi 약물전달 시장은 2024-2030년에 CAGR 19.8%로 성장하며, 2030년에는 33억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 나노입자 약물전달 기술은 CAGR 22.3%를 기록하며, 분석 기간 종료까지 16억 달러에 달할 것으로 예측됩니다. 폐 약물전달 기술 분야의 성장률은 분석 기간 중 CAGR 17.0%로 추정됩니다.

미국 시장은 3억 220만 달러로 추정, 중국은 CAGR 26.3%로 성장 예측

미국의 RNAi 약물전달 시장은 2024년에 3억 220만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 7억 5,560만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 26.3%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 14.4%와 18.0%로 예측됩니다. 유럽에서는 독일이 CAGR 약 15.8%로 성장할 것으로 예측됩니다.

세계의' RNAi 약물전달" 시장 - 주요 동향과 촉진요인 정리

현대 치료에서 RNAi 전달 메커니즘이 중요한 이유는 무엇인가?

RNA 간섭(RNAi)은 유전자 침묵에 혁명을 가져왔고, 질병을 유발하는 유전자를 타의 추종을 불허하는 정확도로 억제할 수 있는 강력한 툴을 제공했습니다. 그러나 RNAi 치료법을 벤치에서 병상으로 옮기기 위한 핵심은 효과적인 전달 시스템에 있습니다. 네이키드 siRNA는 혈류에서 본질적으로 불안정하며, 뉴클레아제에 의해 빠르게 분해되고 신장 여과에 의해 제거되기 쉽습니다. 또한 siRNA는 음전하를 띠고 친수성이기 때문에 세포막을 통과하는 데 큰 장애물이 됩니다. 이러한 문제로 인해 siRNA를 보호할 뿐만 아니라 조직 특이성, 오프타겟 효과의 최소화, 효율적인 세포내 흡수를 보장하는 전달 플랫폼 설계에 대한 연구가 활발히 진행되고 있습니다. 지질 나노입자(LNPs), 고분자 기반 캐리어, 그리고 GalNAc-siRNA와 같은 접합 전략은 이러한 진화에 있으며, 중요한 방법론으로, LNP는 간을 표적으로 하는 데 탁월하고, 고분자 캐리어는 범용성과 구조적 가변성을 제공합니다. 또한 세포외 소포 및 압타머 기반 캐리어는 생물학에서 영감을 받은 면역원성이 낮은 대안으로 부상하고 있습니다. 최적화된 전달 시스템 없이는 RNAi의 치료 가능성은 거의 미개발 상태로 남아 있으며, 따라서 전달 과학은 RNAi 기반 의약품 개발에 있으며, 필수적인 요소로 자리 잡고 있습니다.

지질 나노입자와 폴리머의 혁신은 RNAi 약물전달의 전망을 재구성하고 있는가?

지질 기반 나노입자의 개선은 RNAi 의약품의 임상적 성공을 가능하게 하는 데 핵심적인 역할을 해왔습니다. 특히 유전성 트랜스실레틴 매개 아밀로이드증을 치료하기 위해 LNP를 사용하는 최초의 FDA 승인 siRNA 치료제인 패티실란의 승인은 그 대표적인 예입니다. 이 나노입자는 siRNA를 인캡슐레이션하여 효소 분해로부터 보호하고 표적 세포 내에서 엔도솜으로부터의 탈출을 촉진합니다. 주요 기술 혁신은 이온화 가능한 지질을 강화하여 생체 적합성과 생체내 분포를 개선하고 투여 횟수를 줄일 수 있도록 하는 것이었습니다. 이와 병행하여 폴리에틸렌이민(PEI), 폴리유산-글리콜산(PLGA), 덴드리머와 같은 고분자 기반 시스템이 RNAi 운송에 적합하도록 개선되었습니다. 이러한 시스템들은 적절히 개선될 경우, 방출을 조절하고 전신 독성을 감소시키는 이점이 있습니다. 또한 pH 반응성 고분자나 특정 세포내 환경을 만났을 때 siRNA를 방출하는 자극 민감성 캐리어도 개선되고 있습니다. 지질과 고분자 두 성분을 결합한 하이브리드 시스템 개발은 양자의 장점을 살리는 것을 목표로 하고 있습니다. 또한 호흡기 및 소화기 질환에 대해 국소적이고 비침습적인 전달을 가능하게 하는 점막 및 비강내 전달 시스템을 목표로 하는 연구도 진행되고 있습니다. 전반적으로 LNP와 폴리머의 기술 혁신은 RNAi 치료제의 치료 지표를 다양한 적응증으로 확대하는 데 있으며, 핵심적인 역할을 하고 있습니다.

특정 장기나 질병을 타겟으로 하여 RNAi 전달의 가능성을 극대화할 수 있는가?

RNAi 기반 치료법의 성공 여부는 장기 및 세포 유형 특이성에 따라 달라질 수 있습니다. 간은 울타리 모양의 내피와 나노입자 축적에 대한 자연적 친화력으로 인해 오늘날에도 RNAi 약물의 주요 표적이 되고 있습니다. 간세포의 아세로당단백질수용체(ASGPR) 경로를 이용하는 GalNAc 접합 기술은 siRNA의 피하 전달을 단순화하여 만성 간질환에 대한 간편한 표적 치료를 가능하게 했습니다. 연구자들은 간 적용에 그치지 않고 뇌, 폐, 눈과 같은 도달하기 어려운 조직으로의 전달을 적극적으로 모색하고 있습니다. 혈액뇌장벽(BBB)의 침투는 여전히 큰 장애물이지만, 리간드 표적 나노입자, 마이크로버블을 이용한 집속초음파, 엑소좀 기반 캐리어가 전임상 모델에서 유망한 것으로 나타났습니다. 폐질환의 경우, 비침습적이고 부위 특이적인 투여가 가능한 에어로졸화 RNAi 제제가 각광을 받고 있습니다. 마찬가지로 안구 투여는 생분해성 임플란트 및 하이드로겔 시스템을 통해 지속적 이고 국소적인 유전자 침묵을 가능하게 하는 것이 도움이 되고 있습니다. 암은 여전히 매력적이지만 복잡한 표적입니다. 종양 미세환경의 불균일성과 면역 장벽으로 인해 부위별 축적, 트리거 방출, 최소한의 면역원성을 가진 스마트한 전달 시스템 설계가 필요합니다. 간질환 이외에도 RNAi의 임상적 잠재력을 극대화하기 위해서는 질환별 생리적 기능에 맞게 전달 시스템을 조정하는 것이 필수적입니다.

RNAi 시장의 급격한 확대는 수요 변화와 기술 혁신에 의한 것일까?

세계의 RNAi 약물전달시장 성장은 기술 발전, 최종 사용 패턴의 진화, 소비자 수요의 변화와 관련된 여러 요인에 의해 주도되고 있습니다. 주요 촉진요인은 만성질환 및 유전성 질환의 급격한 증가로 RNAi의 강점인 정밀치료에 대한 긴급한 요구가 발생하고 있습니다. 바이오제약 대기업과 스타트업의 R&D 투자 증가는 임상 파이프라인을 가속화하고 있으며, 일부 RNAi 치료제는 이미 후기 임상시험을 완료한 상태입니다. 또한 고처리 스크리닝 및 생물정보학 툴의 발전으로 새로운 RNAi 표적의 신속한 식별이 가능해져 개발 기간이 단축되고 있습니다. 최종사용자 측면에서는 헬스케어 산업이 맞춤형 의료로 전환하면서 맞춤형 RNAi 치료제에 대한 수요가 증가하고 있습니다. 또한 피하 및 비강과 같은 최소 침습적 투여 경로가 선호되면서 전달 시스템의 기술 혁신이 가속화되고 있습니다. 또한 초기 RNAi 의약품의 상업적 성공은 투자자들의 신뢰를 높여 RNAi 전문 바이오테크 기업에 대한 자금 지원을 증가시키고 있습니다. 규제 당국도 희귀질환을 타겟으로 하는 RNAi 의약품을 조기에 승인하거나 희귀질환으로 지정하는 등 관용적인 태도를 보이고 있습니다. 또한 특히 북미와 유럽에서는 유리한 상환 프레임워크가 환자의 접근성을 확대하고 있습니다. 연구 및 진단 분야에서 RNAi의 채택이 증가함에 따라 시장은 더욱 활성화되고 있으며, 현대 의약품 혁신에서 가장 역동적인 분야 중 하나가 되고 있습니다.

부문

기술(나노입자 약물전달, 폐 약물전달, 핵산 약물전달, 압타머 약물전달), 용도(감염증, 심장병, 종양, 신경, 안과, 비뇨기, 대사질환, 기타 용도)

조사 대상 기업의 예(총 39건)

  • Alnylam Pharmaceuticals
  • Aro Biotherapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • BioNTech SE
  • Dicerna Pharmaceuticals(acquired by Novo Nordisk)
  • DTx Pharma(acquired by Novartis)
  • GlaxoSmithKline(GSK)
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi
  • Sarepta Therapeutics
  • Silence Therapeutics
  • Sirnaomics
  • Switch Therapeutics

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 < gt; 중국 < gt; 멕시코 < gt; 캐나다 < gt; EU < gt; 일본 < gt; 인도 < gt; 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정을 적용하고 있습니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.06.23

Global RNAi Drug Delivery Market to Reach US$3.3 Billion by 2030

The global market for RNAi Drug Delivery estimated at US$1.1 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 19.8% over the analysis period 2024-2030. Nanoparticle Drug Delivery Technology, one of the segments analyzed in the report, is expected to record a 22.3% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Pulmonary Drug Delivery Technology segment is estimated at 17.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$302.2 Million While China is Forecast to Grow at 26.3% CAGR

The RNAi Drug Delivery market in the U.S. is estimated at US$302.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$755.6 Million by the year 2030 trailing a CAGR of 26.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.

Global "RNAi Drug Delivery" Market - Key Trends & Drivers Summarized

What Makes RNAi Delivery Mechanisms So Crucial in Modern Therapeutics?

RNA interference (RNAi) has revolutionized gene silencing, offering a powerful tool to inhibit disease-causing genes with unmatched precision. However, the crux of translating RNAi therapies from bench to bedside lies in effective delivery systems. Naked siRNA is inherently unstable in the bloodstream, prone to rapid degradation by nucleases and clearance via renal filtration. Additionally, siRNAs are negatively charged and hydrophilic, posing a major hurdle to crossing cellular membranes. This challenge has propelled intense research into designing delivery platforms that not only protect siRNA but also ensure tissue specificity, minimal off-target effects, and efficient cellular uptake. Lipid nanoparticles (LNPs), polymer-based carriers, and conjugation strategies like GalNAc-siRNA represent key modalities in this evolution. Each platform comes with distinct advantages-LNPs are excellent for liver targeting, while polymeric carriers offer versatility and structural tunability. Moreover, extracellular vesicles and aptamer-based carriers are emerging as bio-inspired, less immunogenic alternatives. Without optimized delivery systems, the therapeutic potential of RNAi remains largely untapped, hence making delivery science an indispensable pillar in RNAi-based drug development.

Are Innovations in Lipid Nanoparticles & Polymers Reshaping the RNAi Drug Delivery Landscape?

The refinement of lipid-based nanoparticles has taken center stage in enabling clinical success of RNAi drugs, most notably with the approval of patisiran, the first FDA-sanctioned siRNA therapeutic, which uses LNPs to treat hereditary transthyretin-mediated amyloidosis. These nanoparticles encapsulate siRNA, shielding it from enzymatic degradation and facilitating endosomal escape once inside the target cell. Key innovations have involved enhancing ionizable lipids to improve biocompatibility and biodistribution, allowing for reduced dosing frequencies. Parallel to this, polymer-based systems such as polyethyleneimine (PEI), poly(lactic-co-glycolic acid) (PLGA), and dendrimers have been adapted to suit RNAi transport. These offer the advantage of controlled release and reduced systemic toxicity when modified appropriately. Further enhancements include pH-responsive polymers and stimuli-sensitive carriers that release siRNA upon encountering specific intracellular environments. The development of hybrid systems combining both lipid and polymeric components aims to leverage the best features of both. Research is also targeting mucosal and intranasal delivery systems, allowing localized, non-invasive delivery for respiratory or gastrointestinal diseases. Overall, technological innovation in LNPs and polymers is central to expanding the therapeutic index of RNAi therapeutics across a wide range of indications.

Can Targeting Specific Organs and Diseases Unlock the Full Potential of RNAi Delivery?

The success of RNAi-based therapies is increasingly dictated by their capacity for organ and cell-type specificity. The liver, owing to its fenestrated endothelium and natural affinity for nanoparticle accumulation, remains the primary target for RNAi drugs today. GalNAc conjugation technology, which exploits the asialoglycoprotein receptor (ASGPR) pathway in hepatocytes, has simplified subcutaneous delivery of siRNA, enabling convenient and targeted therapy for chronic liver diseases. Beyond hepatic applications, researchers are actively exploring delivery to hard-to-reach tissues such as the brain, lungs, and eyes. Blood-brain barrier (BBB) penetration remains a significant hurdle; however, ligand-targeted nanoparticles, focused ultrasound with microbubbles, and exosome-based carriers are showing promise in preclinical models. In pulmonary conditions, aerosolized RNAi formulations are gaining momentum, offering non-invasive and site-specific administration. Similarly, ocular delivery is benefiting from biodegradable implants and hydrogel systems that allow for sustained, localized gene silencing. Cancer remains a compelling but complex target-tumor microenvironment heterogeneity and immune barriers have necessitated the design of smart delivery systems capable of site-specific accumulation, triggered release, and minimal immunogenicity. Tailoring delivery systems for disease-specific physiology is critical to unlocking RNAi’s full clinical potential beyond hepatic disorders.

Is the Rapid Expansion of the RNAi Market Fuelled by Demand Shifts and Tech Breakthroughs?

The growth in the global RNAi drug delivery market is driven by several factors related to technological advancements, evolving end-use patterns, and shifting consumer demands. A primary driver is the exponential rise in chronic and genetic diseases, which has created an urgent need for precision therapeutics-an area where RNAi excels. Increased R&D investments from biopharma giants and startups alike are accelerating clinical pipelines, with several RNAi therapies already progressing through late-stage trials. Moreover, advances in high-throughput screening and bioinformatics tools are enabling rapid identification of novel RNAi targets, shortening development timelines. On the end-user front, the healthcare industry’s shift toward personalized medicine is boosting demand for customizable RNAi treatments. Additionally, the preference for minimally invasive administration routes-such as subcutaneous and intranasal-has intensified innovation in delivery systems. The commercial success of initial RNAi drugs has also increased investor confidence, triggering more funding toward RNAi-focused biotech firms. Regulatory agencies are becoming more accommodating as well, offering fast-track approvals and orphan designations for RNAi drugs targeting rare diseases. Furthermore, favorable reimbursement frameworks, especially in North America and Europe, are expanding patient access. The increasing adoption of RNAi in research and diagnostics further propels the market, making it one of the most dynamic segments in modern pharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the RNAi Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery, Aptamer Drug Delivery); Application (Infectious Disease, Cardiology, Oncology, Neurology, Ophthalmology, Urology, Metabolic Disorders, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Alnylam Pharmaceuticals
  • Aro Biotherapeutics
  • Arrowhead Pharmaceuticals
  • AstraZeneca
  • BioNTech SE
  • Dicerna Pharmaceuticals (acquired by Novo Nordisk)
  • DTx Pharma (acquired by Novartis)
  • GlaxoSmithKline (GSK)
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi
  • Sarepta Therapeutics
  • Silence Therapeutics
  • Sirnaomics
  • Switch Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • RNAi Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Genetic Disorders Spurs Demand for RNAi-Based Therapeutics
    • Advances in Nanocarrier Technology Strengthen the Business Case for Targeted RNAi Delivery
    • Favorable Regulatory Support for Precision Medicine Drives Adoption of RNAi Platforms
    • Increased Investments in Rare Disease Research Expands Addressable Market Opportunity
    • Growing Pipeline of RNAi Candidates Accelerates Demand for Efficient Delivery Systems
    • Strategic Collaborations Between Biotech and Pharma Companies Propel Growth in RNAi Drug Delivery
    • Breakthroughs in Lipid Nanoparticle Formulations Drive Delivery Efficiency
    • Expanding Role of RNAi in Oncology Throws the Spotlight on Targeted Delivery Innovations
    • High Specificity and Gene Silencing Efficiency Sustain Growth Momentum
    • Government Funding and Public-Private Partnerships Boost RNAi Drug Development
    • Demand for Non-Viral Vectors in Gene Therapy Drives Innovation in Delivery Platforms
    • Development of Inhalable and Oral RNAi Delivery Systems Expands Patient Accessibility
    • Personalized Medicine Trends Reinforce Need for Scalable RNAi Delivery Technologies
    • Overcoming Immunogenicity Challenges Generates New Opportunities in RNAi Formulations
    • Mergers & Acquisitions Accelerate Access to Advanced RNAi Delivery Platforms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World RNAi Drug Delivery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for RNAi Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nanoparticle Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nanoparticle Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Nanoparticle Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pulmonary Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pulmonary Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Pulmonary Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Nucleic Acid Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Nucleic Acid Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Nucleic Acid Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Aptamer Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Aptamer Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Aptamer Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Urology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Urology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Urology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Ophthalmology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Ophthalmology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • JAPAN
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • CHINA
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • EUROPE
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for RNAi Drug Delivery by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • FRANCE
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • GERMANY
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Italy 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: UK 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Spain 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Russia 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for RNAi Drug Delivery by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Australia 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • INDIA
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: India Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: India 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: South Korea 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for RNAi Drug Delivery by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Latin America 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Argentina 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Brazil 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Mexico 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Latin America 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for RNAi Drug Delivery by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for RNAi Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Middle East 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Iran 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Israel 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Saudi Arabia 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: UAE 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Middle East 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030
  • AFRICA
    • RNAi Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for RNAi Drug Delivery by Technology - Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for RNAi Drug Delivery by Technology - Percentage Breakdown of Value Sales for Nanoparticle Drug Delivery, Pulmonary Drug Delivery, Nucleic Acid Drug Delivery and Aptamer Drug Delivery for the Years 2015, 2025 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for RNAi Drug Delivery by Application - Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Africa 15-Year Perspective for RNAi Drug Delivery by Application - Percentage Breakdown of Value Sales for Urology, Metabolic Disorders, Other Applications, Infectious Disease, Cardiology, Oncology, Neurology and Ophthalmology for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제